LEADER 04102nam  2200865Ia 450 
001 9910453419503321
005 20200520144314.0
010   $a1-281-82961-7
010   $a9786611829612
010   $a92-4-068321-6
035   $a(CKB)1000000000544132
035   $a(EBL)367976
035   $a(OCoLC)290068504
035   $a(SSID)ssj0000125266
035   $a(PQKBManifestationID)11132734
035   $a(PQKBTitleCode)TC0000125266
035   $a(PQKBWorkID)10026594
035   $a(PQKB)10974536
035   $a(MiAaPQ)EBC367976
035   $a(Au-PeEL)EBL367976
035   $a(CaPaEBR)ebr10255175
035   $a(CaONFJC)MIL182961
035   $a(OCoLC)549589240
035   $a(EXLCZ)991000000000544132
100   $a20080729d2007      uf             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 10$aCombined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy$b[electronic resource]
210   $aLyon, France $cInternational Agency for Research on Cancer ;$aGeneva $cDistributed by WHO Press$d2007
215   $a1 online resource (543 p.)
225 1 $aIARC monographs on the evaluation of carcinogenic risks to humans ;$vv. 91
300   $aAt head of title: World Health Organization, International Agency for Research on Cancer.
300   $a"This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 7-14 June 2005."
311   $a92-832-1291-6 
320   $aIncludes bibliographical references and cumulative index.
327   $aPreliminaries; CONTENTS; PREAMBLE; Combined Estrogen-Progestogen Contraceptives; Combined Estrogen-Progestogen Menopausal Therapy; ANNEXES; CUMULATIVE INDEX TO THE MONOGRAPHS SERIES;
330   $aOral contraceptives for family planning worldwide have revolutionized the reproductive lives of millions of women since their introduction in the 1960's. Later on, a variety of side-effects including cardiovascular diseases was recognized. In response to these concerns, new generations of combined oral contraceptives were developed that featured lower dose of estrogen and newer, more potent progestogens. The effectiveness and ease of use of combined hormonal contraceptives suggest that they will continue to be used to a significant extent in the future. This ninety-first volume of IARC Monographs
410  0$aIARC monographs on the evaluation of carcinogenic risks to humans ;$vv. 91.
606   $aProgestational hormones$xCarcinogenicity
606   $aProgestational hormones$xSide effects
606   $aCatechol estrogens$xCarcinogenicity
606   $aEstrogen$xCarcinogenicity
606   $aCatechol estrogens$xSide effects
606   $aEstrogen$xSide effects
606   $aContraception$xComplications
606   $aMenopause$xHormone therapy$xComplications
606   $aChemical carcinogenesis
606   $aCancer$xRisk factors
606   $aWomen$xDiseases$xRisk factors
606   $aOral contraceptives$xCarcinogenicity
608   $aElectronic books.
615  0$aProgestational hormones$xCarcinogenicity.
615  0$aProgestational hormones$xSide effects.
615  0$aCatechol estrogens$xCarcinogenicity.
615  0$aEstrogen$xCarcinogenicity.
615  0$aCatechol estrogens$xSide effects.
615  0$aEstrogen$xSide effects.
615  0$aContraception$xComplications.
615  0$aMenopause$xHormone therapy$xComplications.
615  0$aChemical carcinogenesis.
615  0$aCancer$xRisk factors.
615  0$aWomen$xDiseases$xRisk factors.
615  0$aOral contraceptives$xCarcinogenicity.
712 02$aWorld Health Organization.
712 02$aInternational Agency for Research on Cancer.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910453419503321
996   $aCombined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy$91987231
997   $aUNINA